Zimmer Biomet Holdings Inc (NYSE:ZBH) – Equities research analysts at Svb Leerink dropped their Q2 2019 EPS estimates for shares of Zimmer Biomet in a report issued on Wednesday, July 10th. Svb Leerink analyst R. Newitter now forecasts that the medical equipment provider will post earnings of $1.92 per share for the quarter, down from their prior forecast of $1.96. Svb Leerink also issued estimates for Zimmer Biomet’s Q4 2019 earnings at $2.28 EPS and FY2021 earnings at $8.97 EPS.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Friday, April 26th. The medical equipment provider reported $1.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.86 by $0.01. Zimmer Biomet had a negative net margin of 3.90% and a positive return on equity of 13.24%. The company had revenue of $1.98 billion for the quarter, compared to the consensus estimate of $1.97 billion. During the same quarter last year, the firm posted $1.91 earnings per share. The firm’s revenue was down 2.1% compared to the same quarter last year.

Several other brokerages also recently weighed in on ZBH. TheStreet downgraded shares of Zimmer Biomet from a “b-” rating to a “c” rating in a report on Friday, June 7th. Cantor Fitzgerald set a $135.00 price target on shares of Zimmer Biomet and gave the company a “buy” rating in a report on Friday, April 26th. Evercore ISI raised shares of Zimmer Biomet from an “in-line” rating to an “outperform” rating and set a $145.00 price target on the stock in a report on Monday, April 8th. Zacks Investment Research raised shares of Zymeworks from a “hold” rating to a “buy” rating and set a $18.00 price target on the stock in a report on Saturday, April 13th. Finally, Needham & Company LLC lifted their price target on shares of CoStar Group from $500.00 to $600.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $131.41.

Shares of NYSE:ZBH opened at $120.60 on Friday. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.00 and a quick ratio of 0.97. Zimmer Biomet has a 1-year low of $96.99 and a 1-year high of $134.55. The stock has a market capitalization of $24.78 billion, a P/E ratio of 15.79, a P/E/G ratio of 2.26 and a beta of 1.14. The firm’s 50 day moving average price is $117.55.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. increased its position in Zimmer Biomet by 3.2% in the first quarter. BlackRock Inc. now owns 16,474,877 shares of the medical equipment provider’s stock worth $2,103,841,000 after purchasing an additional 509,160 shares during the last quarter. American Century Companies Inc. increased its position in Zimmer Biomet by 23.1% in the fourth quarter. American Century Companies Inc. now owns 5,425,619 shares of the medical equipment provider’s stock worth $562,745,000 after purchasing an additional 1,016,489 shares during the last quarter. OppenheimerFunds Inc. increased its position in Zimmer Biomet by 7.9% in the first quarter. OppenheimerFunds Inc. now owns 3,156,333 shares of the medical equipment provider’s stock worth $403,063,000 after purchasing an additional 231,307 shares during the last quarter. Geode Capital Management LLC increased its position in Zimmer Biomet by 8.4% in the fourth quarter. Geode Capital Management LLC now owns 2,641,717 shares of the medical equipment provider’s stock worth $273,516,000 after purchasing an additional 205,532 shares during the last quarter. Finally, Primecap Management Co. CA increased its position in Zimmer Biomet by 29.4% in the first quarter. Primecap Management Co. CA now owns 2,463,720 shares of the medical equipment provider’s stock worth $314,617,000 after purchasing an additional 559,370 shares during the last quarter. Institutional investors own 88.56% of the company’s stock.

In other news, insider Sang Yi sold 426 shares of Zimmer Biomet stock in a transaction that occurred on Friday, May 24th. The shares were sold at an average price of $114.88, for a total transaction of $48,938.88. Following the sale, the insider now owns 1,457 shares in the company, valued at $167,380.16. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 0.72% of the company’s stock.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 31st. Stockholders of record on Friday, June 28th will be given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 0.80%. The ex-dividend date of this dividend is Thursday, June 27th. Zimmer Biomet’s payout ratio is currently 12.57%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Recommended Story: Strangles

Earnings History and Estimates for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.